![Hans-Ulrich Demuth](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hans-Ulrich Demuth
Plus aucun poste en cours
Historique de carrière de Hans-Ulrich Demuth
Anciens postes connus de Hans-Ulrich Demuth
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIVORYON THERAPEUTICS N.V. | Directeur Technique/Scientifique/R&D | 01/12/1997 | 31/01/2013 |
Fondateur | 25/07/1997 | 31/01/2013 | |
Hochschule Anhalt | Corporate Officer/Principal | - | - |
Ingenium Pharmaceuticals GmbH
![]() Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Directeur Général | 04/11/2009 | - |
Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - | - |
Formation de Hans-Ulrich Demuth
Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Statistiques
Internationale
Allemagne | 4 |
2 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Consumer Services | 3 |
Commercial Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
VIVORYON THERAPEUTICS N.V. | Health Technology |
Entreprise privées | 1 |
---|---|
Ingenium Pharmaceuticals GmbH
![]() Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
- Bourse
- Insiders
- Hans-Ulrich Demuth
- Expérience